Persistent Atrial Fibrillation When Rate Control Has Not Achieved Target Heart Rate

Persistent AF — defined by AF episodes that are not self-terminating — requires a reassessment of strategy when rate control alone has not restored adequate heart rate targets or continues to leave the patient symptomatic.

Previous approach & failure condition Rate control with a single agent was the first-line strategy, targeting a resting heart rate below 110 b.p.m. (lenient control), with stricter control in patients with continuing symptoms. When this heart rate goal is not met — or symptoms persist despite it — escalation to a rhythm control approach is the next clinical step.
Clinical scenario Persistent atrial fibrillation: AF episodes that do not terminate on their own, representing a sustained arrhythmia requiring active intervention to restore and maintain sinus rhythm.
Treatment approach (partial) The next step is a rhythm control strategy. This may involve cardioversion and/or antiarrhythmic drug therapy, with the specific agent determined by the patient's underlying cardiac status. Catheter ablation may also be an option in selected cases. The complete algorithm — including agent selection, sequencing, and patient-specific considerations — is available in the full protocol.
Clinical goals Maintenance of sinus rhythm and reduction of AF-related symptoms.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehae176

  • AF episodes which are not self-terminating.
  • Cardioversion of AF (either electrical or pharmacological) should be considered in symptomatic patients with persistent AF as part of a rhythm control approach.
  • Amiodarone is recommended in patients with AF and HFrEF requiring long-term antiarrhythmic drug therapy to prevent recurrence and progression of AF, with careful consideration and monitoring for extracardiac toxicity.
  • Dronedarone is recommended in patients with AF requiring long-term rhythm control, including those with HFmrEF, HFpEF, ischaemic heart disease, or valvular disease to prevent recurrence and progression of AF.
  • Flecainide or propafenone is recommended in patients with AF requiring long-term rhythm control to prevent recurrence and progression of AF, excluding those with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease.
  • Catheter ablation may be considered as a first-line option within a shared decision-making rhythm control strategy in selected patients with persistent AF to reduce symptoms, recurrence, and progression of AF.
View source ↗